Shanghai Rui Touch Robot Files Hong Kong IPO with RMB 3.07 Billion Post-Money Valuation

According to Hong Kong Stock Exchange disclosure, Shanghai Rui Touch Robot has filed for main board listing with exclusive sponsor China Everbright Securities International, recently. The company achieved a post-money valuation of RMB 3.07 billion following its Series B funding round completed in September 2025.

The company's core product RC120 percutaneous puncture surgical robot obtained third-category medical device approval in 2024 and has been deployed in 39 hospitals nationwide as of late November 2025. However, the robot generated zero revenue in 2024 and the first half of 2025, following only RMB 156,000 in revenue during 2023 from one-time technical support services. Cumulative net losses reached RMB 89.33 million, with annual losses of RMB 34.2 million (2023), RMB 37 million (2024), and RMB 18.1 million (first half 2025).